Replies to post #811 on Versartis, Inc. (VSAR)

[Wildbilly]

Aravive FDA fast track designation pr

Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

http://aravive.com/press-releases/u-s-fda-grants-fast-track-designation-to-aravive-biologics-avb-s6-500/